Parameter | Number of cases | Survival (months) | p-value |
---|---|---|---|
n (%) | median (95 % CI) | ||
Eag1 expression | |||
High | 39 (52 %) | 6 (3 – 8.1) | |
Low | 36 (48 %) | 11 (7 – 13.7) | 0.012 |
Antidepressants | |||
(amitriptyline/citalopram) | |||
Eag1 high | |||
Treated | 8 (10.7 %) | 6 (3 – 9.9) | |
Untreated | 27 (36 %) | 6 (3 – 9) | 0.1 |
Eag1 low | |||
Treated | 10 (13.3 %) | 13 (6.1 – 22.8) | |
Untreated | 25 (33.3 %) | 10 (7 – 14.7) | 0.03 |
Gender | |||
Male | |||
Eag1 high | 26 (34.7 %) | 6.2 (3.9 – 8.5) | |
Eag1 low | 13 (17.3) | 10.6 (6.4 – 14.8) | 0.039 |
Female | |||
Eag1 high | 13 (17.3 %) | 10.15 (6.1– 14.2) | |
Eag1 low | 23 (30.7 %) | 11.65 (9 – 14.3) | 0.5 |
Tumor localization of brain metastases | |||
Fronto-parietal | |||
Eag1 high | 18 (24 %) | 6.5 (3 – 10) | |
Eag1 low | 17 (22.7 %) | 10 (7 – 16.9) | 0.15 |
Temporo-occipital | |||
Eag1 high | 10 (13.3 %) | 6.5 (3 – 14.1) | |
Eag1 low | 6 (8 %) | 8.5 (5.2 – 16.2) | 0.6 |
Cerebellar | |||
Eag1 high | 11 (14.7 %) | 5 (2.8 – 8.2) | |
Eag1 low | 13 (17.3 %) | 13 (5.6 – 16.4) | 0.03 |